Projects
The pharmaceutical projects listed in this phase are those that receive periodic global announcements.
Abzena Invests $5 Million to Expand Bioconjugation and ADC Capabilities
Abzena, a leading CDMO for complex biologics and bioconjugates, announced a significant expansion of its Bristol, PA site for bioconjugate development and cGMP manufacturing
Sandoz Breaks Ground on New Antibiotic Production Facility in Austria with EUR 50 Million Investment
Sandoz, a global leader in generic and biosimilar medicines, opens new production facility in Kundl, Austria Facility aims to provide affordable lifesaving drugs solely manufactured in Europe,
AbbVie Invests $223 Million to Enhance Biologics Manufacturing Capacity at Singapore Site
AbbVie commenced the construction of a new expansion at its Singapore manufacturing facility, emphasizing its commitment
AGC Biologics to Break Ground on New 50 Billion Yen Manufacturing Site in Yokohama, Japan
AGC Biologics is planning to build a new manufacturing facility at AGC Incs Yokohama Technical Center in Japan This expansion is part of AGC Biologics strategic growth strategy to enhance pharmaceutical development
Fujifilm Invest $200 Million to Advance Cell Therapy Development and Expand Manufacturing
FUJIFILM Cellular Dynamics, specializing in human induced pluripotent stem cells and iPSCderived cells, and FUJIFILM Diosynth Biotechnologies in California, a prominent CDMO in biologics and advanced therapies,
Eli Lilly Reveals Plans for a $2.5 Billion Investment to Expand Injectable Manufacturing Capacity in Germany
Eli Lilly and Company plans to build a hightech manufacturing facility in Alzey, Rhineland Palatinate, Germany
Aragen Unveils Groundbreaking $30 Million Investment for Bio-Manufacturing Facility in India
Aragen, a leading CRDMO specializing in small molecules and biologics, is establishing a new biologics manufacturing facility in Bangalore, India
Bayer Invests $250 Million in First Global Cell Therapy Manufacturing Facility for Regenerative Medicines
The facility aims to produce cell and gene therapies on a global scale, making them more accessible worldwide
Sandoz Invests $90 Million in Advanced Biosimilar Technical Development CenterIntroduction
Sandozs investment sets the stage for a significant transformation of the Ljubljana site into a central hub for advancing biosimilar products within the company
Novo Nordisk Foundation Invests EUR 127 Million in Advancing Human Cell Therapy Scaling
The Novo Nordisk Foundation is embarking on a groundbreaking journey, dedicating its resources to forge a stateoftheart facility that will serve as the ultimate crucible
